LIVE

DNLI

Denali Therapeutics Inc.

DNLI

NASDAQ·Healthcare·Biotechnology·Mkt cap $4.1B

$25.83

▼ -0.58%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$12.58 - $26.80

P/E

-8.97

Fwd P/E

-9.20

Beta

1.01

Div Yield

0.00%

Avg Vol

1.8M

Shares Out

158.6M

Mkt Cap

$4.1B

Price action

Price chart

Up 74.4% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

5 reasons

  • Strategic partnerships with pharmaceutical giants (Takeda, Genentech, Sanofi) providing capital and expertise
  • Proprietary LRRK2 inhibitor platform with clinical validation in Parkinson's disease
  • Diversified pipeline targeting multiple neurodegenerative indications reducing development risk
  • Collaboration with leading research institutions and patient advocacy organizations (Michael J. Fox Foundation)
  • Antisense therapy research agreement with Secarna Pharmaceuticals expanding therapeutic modalities
▼

Bear Case

1 risk

  • Average volatility.

Growth

Revenue decline expected

Growing mid-cap in Biotechnology

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Hot

+25.8% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 4, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of -$0.69 vs -$0.73 consensus (+5.5% surprise).

EPS beat +5.5%

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+5.5%

Next: May 4, 2026

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

10 analysts · 90% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

9

90%

Hold

1

10%

Sell

0%

Median Price Target

$33.00

▲ +27.8% vs $25.83

Low $23.00
Median $33.00
High $35.00

Latest: Bernstein · Jun 22, 2026

3 analysts covering

View full analyst page →

vs Industry

How DNLI stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.